NCT01859026 2023-01-19A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR MutationH. Lee Moffitt Cancer Center and Research InstitutePhase 1 Completed43 enrolled